13.47

16.83% 1.94

After Hours: 13.40 -0.07 -0.52%

Immunome Inc (IMNM)

Overview News Price History Option Chain Financials Discussions Forecast

Immunome Inc stock is traded at $13.47, with a volume of 1.38M. It is up +16.83% in the last 24 hours and up +11.23% over the past month. Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Previous Close:

$11.53

Open:

$11.68

24h Volume:

1.38M

Relative Volume:

1.87

Market Cap:

$719.67M

Revenue:

Net Income/Loss:

$-106.81M

P/E Ratio:

-6.1227

EPS:

-2.2

Net Cash Flow:

$-8.40M

1W Performance:

+44.37%

1M Performance:

+11.23%

6M Performance:

-5.27%

1Y Performance:

+70.08%

1-Day Range:

$11.62

$13.53

1-Week Range:

$9.05

$13.53

52-Week Range:

$6.93

$30.96

Immunome Inc Stock (IMNM) Company Profile

Name

Immunome Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

610-321-3700

Address

18702 N. CREEK PARKWAY, BOTHELL

Employee

105

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMNM's Discussions on Twitter

Compare IMNM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMNM Immunome Inc	13.47	719.67M	0	-106.81M	-8.40M	-2.20
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-31-24	Initiated	Piper Sandler	Overweight
Apr-30-24	Initiated	JP Morgan	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Jan-29-24	Initiated	Leerink Partners	Outperform
Dec-19-23	Initiated	Wedbush	Outperform
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight

View All

Immunome Inc Stock (IMNM) Latest News

Nov 27, 2024

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - The Bakersfield Californian

Nov 27, 2024

President of Immunome Picks Up 24% More Stock - Simply Wall St

Nov 27, 2024

Nov 26, 2024

Why Is Immunome Inc (NASDAQ: IMNM) Gaining? - Stocks Register

Nov 26, 2024

Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World

Nov 26, 2024

Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts - MarketBeat

Nov 26, 2024

Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - Defense World

Nov 26, 2024

Nov 25, 2024

Immunome's chief medical officer Robert Lechleider buys $149,799 in stock - Investing.com India

Nov 25, 2024